Research Analysts Set Expectations for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Investment analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, September 29th. Chardan Capital analyst R. Li forecasts that the company will post earnings per share of ($0.40) for the year. Chardan Capital has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03.

Several other analysts also recently commented on RVPH. Maxim Group reduced their price target on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Roth Capital restated a “buy” rating and issued a $3.00 price objective (down from $7.00) on shares of Reviva Pharmaceuticals in a research note on Monday, August 18th. Citigroup restated a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, August 16th. Finally, Benchmark dropped their price target on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research note on Monday, September 15th. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $4.86.

Reviva Pharmaceuticals Stock Up 35.1%

NASDAQ:RVPH opened at $0.49 on Thursday. The company has a market capitalization of $33.82 million, a PE ratio of -0.75 and a beta of -0.08. Reviva Pharmaceuticals has a 52-week low of $0.25 and a 52-week high of $4.28. The stock’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.63.

Institutional Trading of Reviva Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the last quarter. BluePointe Capital Management LLC lifted its stake in Reviva Pharmaceuticals by 354.7% in the 1st quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock valued at $45,000 after buying an additional 36,807 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Reviva Pharmaceuticals during the 4th quarter valued at $84,000. NewEdge Advisors LLC purchased a new position in Reviva Pharmaceuticals during the first quarter worth $58,000. Finally, XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals in the second quarter worth $31,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.